Vaccine against tick-borne encephalitis for adults (TicoVac 0.5ml) and children (TicoVac 0.25ml)

Tick-borne encephalitis (TBE) – is a serious natural focal viral disease caused by the tick-borne encephalitis virus (TBEV), affecting the brain, its membranes, or peripheral nerves. TBE is one of the most important viral infections of the human central nervous system, characterized by residual phenomena, sometimes causing disability. TBE is prevalent in many countries around the world. TBE was first described in 1927 in Austria, and the causative agent of this disease – TBEV was isolated in 1937 in the former Soviet Union.

According to ULAC data, the mortality rate from TBE is 0.5-4%. About one-third of people who have had TBE do not fully recover. The most common residual effects include: inability to concentrate, sleep disorders, persistent headaches, increased sensitivity, behavioral changes. Less often – paresis (paralysis).

The most effective preventive measure against TBE – vaccination. TBE vaccines can be administered to children older than 1 year. There are two vaccination schedules: regular and accelerated. The first two doses of the regular vaccination schedule are administered at 1-3 month intervals; the intervals for the third and booster doses may vary depending on the vaccine manufacturer and are indicated in the vaccine information leaflet. After full vaccination (3 doses), about 97% of vaccinated individuals develop a protective antibody titer.